Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - trastuzumab, quantity: 440 mg - injection, powder for - excipient ingredients: histidine hydrochloride; histidine; polysorbate 20; trehalose dihydrate - early breast cancer simabtra? is indicated for the treatment of her2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,locally advanced breast cancer simabtra? is indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant simabtra?.,metastatic breast cancer simabtra? is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or c) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormonereceptor positive metastatic breast cancer.,advanced gastric cancer simabtra? is indicated in combination with cispla

Israel - English - Ministry of Health

amgen europe b.v. - trastuzumab - powder for concentrate for solution for infusion - trastuzumab 150 mg/vial - trastuzumab - metastatic breast cancer (mbc)kanjinti is indicated for the treatment of patients with metastatic breast cancer who have tumors that overexpress her2;1. as a single agent, for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease.2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.3. in combination with an aromatase inhibitor for the treatment of postmenopausal patient with hormone-receptor positive metastatic breast cancer.early breast cancer (ebc)kanjinti is indicated to treat patients with her2 positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines.kanjinti should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)kanjinti in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with her2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.kanjinti should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc 2+ and a confirmatory fish+ result, or ihc 3+, as determined by an accurate and validated assay.

Israel - English - Ministry of Health

amgen europe b.v. - trastuzumab - powder for concentrate for solution for infusion - trastuzumab 420 mg/vial - trastuzumab - metastatic breast cancer (mbc)kanjinti is indicated for the treatment of patients with metastatic breast cancer who have tumors that overexpress her2;1. as a single agent, for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease.2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.3. in combination with an aromatase inhibitor for the treatment of postmenopausal patient with hormone-receptor positive metastatic breast cancer.early breast cancer (ebc)kanjinti is indicated to treat patients with her2 positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines.kanjinti should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)kanjinti in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with her2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.kanjinti should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc 2+ and a confirmatory fish+ result, or ihc 3+, as determined by an accurate and validated assay.

Canada - English - Health Canada

astrazeneca canada inc - trastuzumab deruxtecan - powder for solution - 100mg - trastuzumab deruxtecan 100mg - antineoplastic agents

Israel - English - Ministry of Health

dexcel ltd, israel - trastuzumab - powder and solvent for concentrate for solution for infusion - trastuzumab 420 mg/vial - trastuzumab - ogivri is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :ogivri is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. ogivri should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc).ogivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.ogivri should only be used in patients with metastatic gastric cancer whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory fish+ result, or ihc 3+, as determined by an accurate and validated assay.

United States - English - NLM (National Library of Medicine)

genentech, inc. - pertuzumab (unii: k16aiq8ctm) (pertuzumab - unii:k16aiq8ctm), trastuzumab (unii: p188anx8ck) (trastuzumab - unii:p188anx8ck), hyaluronidase (human recombinant) (unii: 743quy4vd8) (hyaluronidase (human recombinant) - unii:743quy4vd8) - phesgo is indicated for use in combination with chemotherapy for - the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see dosage and administration (2.2) and clinical studies (14.2)] . - the adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrence [see dosage and administration (2.2) and clinical studies (14.2)] . select patients for therapy based on an fda-approved companion diagnostic test [see dosage and administration (2.1)]. phesgo is indicated for use in combination with docetaxel for the treatment of adult patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease [see dosage and administration (2.2) and clinical studies (14.1)] . select patients for therapy based on an fda-approved compa

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - trastuzumab, quantity: 65 mg - injection, powder for - excipient ingredients: polysorbate 20; trehalose dihydrate; histidine; histidine hydrochloride monohydrate - early breast cancer,kanjinti is indicated for the treatment of her2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,locally advanced breast cancer,kanjinti is indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant kanjinti.,metastatic breast cancer,kanjinti is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2:,a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;,b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.,advanced gastric cancer,kanjinti is indicated in combination with cisplatin and either capecitabine or 5-fu for the treatment of patients with her2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

herceptin) 42mg/250ml in sodium chloride 0.9% infusion bags (special order - trastuzumab - infusion - 168microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

herzuma) 42mg/250ml in sodium chloride 0.9% infusion bags (special order - trastuzumab - infusion - 168microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kanjinti) 42mg/250ml in sodium chloride 0.9% infusion bags (special order - trastuzumab - infusion - 168microgram/1ml